Wellnex Life reports 46% revenue surge in recent trading update

SYDNEY - Wellnex Life Limited (ASX:WNX AIM:WNX), an Australian consumer healthcare company, has reported a significant increase in revenue and gross margins for the period from January to April 2025. The company, known for developing and marketing health-related products and brands, announced a 46% revenue growth compared to the same period in the previous year.

During the four-month period, Wellnex Life generated $8.0 million in revenue, a substantial rise from the $5.4 million recorded in the prior comparable period (PCP). Gross margins followed suit, increasing by 55% to $2.99 million, up from $1.93 million in the PCP.

The company also highlighted a particularly strong performance in April 2025, with revenues soaring 75% to $2.57 million and gross margins growing by 74% to $1.13 million, compared to April 2024.

Despite a slower start to the fiscal year 2025 due to product stock outages, delays in new product deliveries, and the initial public offering (IPO) process, Wellnex Life has since overcome these challenges. The fiscal year-to-date revenue stood at $19.9 million with gross margins of $5.7 million. The company noted that these figures were impacted by a strategic increase in trade investment in the first half of the fiscal year, which temporarily reduced gross margins to 22%. However, trade investment has returned to normal levels, resulting in improved gross margins of approximately 37% for the reported period.

The company successfully listed on the AIM Market of the London Stock Exchange (LON:LSEG) on March 21, 2025, using the funds raised to pay off approximately $13 million in debt, leading to direct savings of around $1.4 million in annual costs.

Looking forward, Wellnex anticipates continued growth across its business for the remainder of FY25 and into FY26, driven by increasing demand for its products and an expansion of its brands in the Australian market. Plans are also underway to enter the UK and European markets in FY26. The company aims to optimize its trade investment strategy and reduce operational expenses to enhance future performance.

Joint CEO Director Zack Bozinovski expressed confidence in the ongoing growth across the company’s brands and IP licensing opportunities, which he believes will positively impact Wellnex’s future performance. The company’s improved financial position following the AIM listing and debt reduction is expected to support its expansion in the growing consumer healthcare market.

This news is based on a press release statement from Wellnex Life Limited.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.